Thymalfasin for Injection – Adjuvant for Influenza Vaccine

Thymalfasin for Injection Application Scope

The new and special drug Thymalfasin for Injection can be used to treat chemotherapy-induced immunosuppression and to improve the efficacy of influenza and hepatitis B vaccines in immunocompromised patients.

1. Chronic Hepatitis B.
2. Enhancing vaccine immune response in immunocompromised patients, including those undergoing chronic hemodialysis or elderly patients. This product can improve immune responses to viral vaccines, such as influenza or hepatitis B vaccines.

Thymalfasin for Injection Characteristics

• Ingredients: Thymalfasin (Thymosin Alpha-1) and other small molecular peptides.
• Properties: This product appears as a white, loose, block-like substance.
• Specification: 1.6 mg per vial.
• Packaging Specification: 10 vials per box.
• Storage: Keep tightly sealed and store in a cool, dark place.
• Expiry Date: Not specified.
• Executive Standard: Not specified.
• Approval Number: GuoYaoZhunZi H20051916.
• Date of Revision: Specify based on the product version.
• Manufacturer: Hainan Zhonghe Pharmaceutical Co., Ltd.

Guidelines For The Use Of Thymalfasin for Injection

Dosage and Administration:

• Subcutaneous or Intramuscular Injection: 10–20 mg once daily or as directed by a physician.
• Intravenous Infusion: 20–80 mg dissolved in 500 ml of 0.9% sodium chloride injection or 5% glucose injection, administered once daily or as directed by a physician.

Adverse Reactions:
Currently unknown.

Medication Limitations

Contraindications:
Patients with a positive reaction to this drug should not use it.

Precautions:

1. For individuals with allergic constitutions, a skin sensitivity test (intradermal injection of 0.1 ml of a 25 μg/ml solution) is required before the first dose or if treatment is resumed after discontinuation. Patients with a positive reaction should avoid using this drug.
2. Do not use it if the product appears cloudy or contains abnormal precipitates.

Thymalfasin for Injection Interactions

No known drug interactions have been identified.

 

Note: If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYueMed. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.